Since December 31st, 2007, Abbott Laboratories's enterprise value to ebitda (ev/ebitda) has increased from 5.95 to 16.41 at May 24th, 2022.
Abbott Laboratories's enterprise value to ebitda (ev/ebitda) as of May 24th, 2022 of 16.41 was lower than its peers in the Medical Appliances & Equipment industry group of April 30th, 2022 of 115,807.76. From December 31st, 2007 to May 24th, 2022, Abbott Laboratories's average enterprise value to ebitda (ev/ebitda) was 13.77 compared to an industry average of 3,374.09.
Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure and other medical device products. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
© 2021 DiscoverCI
Disclaimer: DiscoverCI LLC is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on DiscoverCI.com represent a recommendation to buy or sell a security. The information on this site, and in its related application software, spreadsheets, blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. In no event shall DiscoverCI.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any product, content or other material published or available on DiscoverCI.com, or relating to the use of, or inability to use, DiscoverCI.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.